Anti-IL1RAP Antibodies and Their Use for Treating Humans
AssigneeCantargia AB
InventorsThoas Fioretos, Marcus Järås
Life of this patent
Estimating the term…
Loading patent…
AssigneeCantargia AB
InventorsThoas Fioretos, Marcus Järås
Estimating the term…
The present invention provides agents comprising or consisting of a binding moiety with specificity for interleukin-1 receptor accessory protein (IL1RAP) for use in inducing cell death and/or inhibiting the growth and/or proliferation of cells associated with a solid tumour, wherein the cells express IL1RAP. A related aspect of the invention provides agents comprising or consisting of a binding moiety with specificity for interleukin-1 receptor accessory protein (IL1RAP) for use in detecting pathological cells associated with a solid tumour, wherein the cells express IL1RAP. Further provided are pharmacological compositions comprising the agents of the invention and methods of using the same.
An agent comprising or consisting of a binding moiety with specificity for interleukin-1 receptor accessory protein (IL1RAP) for use in inducing cell death and/or inhibiting the growth and/or proliferation of cells associated with a solid tumour, wherein the cells express IL1RAP.
An agent comprising or consisting of a binding moiety with specificity for interleukin-1 receptor accessory protein (IL1RAP) for use in detecting cells associated with a solid tumour, wherein the cells express IL1RAP.
An agent according to any one of the preceding claims wherein the solid tumour is selected from the group consisting of cancers of the prostate, breast, skin, colon, lung, urinary organs and uterus.
An agent according to any one of the preceding claims wherein the solid tumour is selected from the group consisting of prostate cancer, melanomas, cervical cancer, oesophageal cancer, and head and/or neck cancer.
An agent according to any one of the preceding claims wherein the binding moiety has specificity for human IL1RAP.
An agent according to any one of the preceding claims wherein IL1RAP is localised on the surface of a cell.
An agent according to any one of the preceding claims wherein the agent is capable of blocking binding of one or more co-receptors to IL1RAP.
An agent according to any one of the preceding claims wherein the agent is capable of killing the cells associated with the solid tumour.
An agent according to any one of the preceding claims wherein the agent comprises or consists of a polypeptide.
An agent according to any one of the preceding claims wherein the agent comprises or consists of an antibody or antigen-binding fragment thereof.
An agent according to any one of the preceding claims wherein the antibody or antigen-binding fragment thereof is human or humanised.
An agent according to any one of the preceding claims further comprising a moiety for increasing the in vivo half-life of the agent.
An agent according to any one of the preceding claims further comprising a cytotoxic moiety.
An agent according to any one of the preceding claims further comprising a detectable moiety.
An agent for use in medicine substantially as described herein with reference to the description.
A pharmaceutical composition substantially as described herein with reference to the description.
Use of an agent substantially as described herein with reference to the description.
A method of treatment or diagnosis as described herein with reference to the description.
A kit substantially as defined herein with reference to the description.
Dependencies are inferred from the claim text.